SCHEMBL17959000

SCHEMBL17959000

O=C(NO)c1ccc2c(c1)CCN(Cc1ccccc1)CCO2

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 12/20 0.61
▸ HDAC6 Q9UBN7 12/20 0.61
▸ HDAC4 P56524 5/20 0.58
▸ KCNH2 Q12809 1/20 0.58
▸ ACHE P22303 2/20 0.53
▸ HDAC8 Q9BY41 5/20 0.53
▸ HDAC3 O15379 4/20 0.53
▸ HDAC7 Q8WUI4 4/20 0.53
▸ HDAC2 Q92769 4/20 0.53
▸ HDAC10 Q969S8 4/20 0.53
▸ HDAC11 Q96DB2 4/20 0.53
▸ HDAC9 Q9UKV0 4/20 0.53
▸ HDAC5 Q9UQL6 4/20 0.53
▸ ALDH1A1 P00352 2/20 0.51
▸ PKM P14618 1/20 0.51
▸ SLC6A12 P48065 1/20 0.50
▸ SLC6A13 Q9NSD5 1/20 0.50
▸ FAAH O00519 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17958997 0.91 HDAC1 (0.61) HDAC1HDAC6HDAC4KCNH2ACHE
SCHEMBL17959014 0.83 HDAC6 (0.57) HDAC1HDAC6HDAC4KCNH2ACHE
SCHEMBL20928509 0.83 HDAC1 (0.56) HDAC1HDAC6HDAC4KCNH2ACHE
SCHEMBL17959036 0.81 HDAC6 (0.47) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL1264338 0.80 HDAC6 (0.65) HDAC1HDAC6HDAC4KCNH2HDAC8
SCHEMBL17959039 0.80 HDAC6 (0.64) HDAC1HDAC6HDAC4HDAC8HDAC3
SCHEMBL18581608 0.78 HDAC1 (0.65) HDAC1HDAC6HDAC4KCNH2ACHE
SCHEMBL14023200 0.78 ALDH1A1 (0.53) HDAC1HDAC6ACHEALDH1A1PKM
SCHEMBL17958999 0.77 HDAC6 (0.51) HDAC6ALDH1A1PKM
SCHEMBL17959056 0.77 HDAC6 (0.57) HDAC1HDAC6HDAC4KCNH2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-12-22 — — US claimed
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2019-11-14 — — US claimed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO claimed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US claimed
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2025-05-20 — — US disclosed
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2023-11-09 — — US disclosed
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2023-07-18 — — US disclosed
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS VALO HEALTH, INC. 2021-07-08 — — US disclosed
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-12-22 — — US disclosed
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2019-11-14 — — US disclosed
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-10 — — US disclosed
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-28 — — US disclosed
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-22 — — US disclosed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO disclosed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 7/4885HDAC4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback